コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 -month mean follow-up, 2 were treated with a melanoma vaccine.
2 ts T-cell immune responses to a multipeptide melanoma vaccine.
3 tractive components for a widely efficacious melanoma vaccine.
4 eptides augment CD8(+) T-cell responses to a melanoma vaccine and whether cyclophosphamide (CY) pretr
5 and gp100(614-622) epitopes in peptide-based melanoma vaccines and thus expands the list of immunogen
7 this new knowledge, many clinical trials of melanoma vaccines are now under way, and vaccines for me
8 trial of adjuvant therapy with a whole-cell melanoma vaccine, Canvaxin, plus Bacille Calmette-Guerin
9 ate the safety and immunogenicity of a novel melanoma vaccine comprising six melanoma-associated pept
12 n tumor vaccine-draining lymph nodes after a melanoma vaccine given to RAG1 mice reconstituted with n
13 Thus, tyrosinase provides a model for anti-melanoma vaccines in which a single molecule can generat
14 f tumor regression in the face of observable melanoma vaccine-induced T cell responses might be attri
15 ely called M5) and response to an allogeneic melanoma vaccine (Melacine; Corixa Corporation, Seattle,
16 d how to make K1735 cells, a poor allogeneic melanoma vaccine, more effective for protection against
17 tined to experience treatment failure with a melanoma vaccine (MV) previously shown to improve surviv
18 cally decreased CD8(+) T-cell responses to a melanoma vaccine (P < .001), and CY pretreatment had no
20 MHC II)-matched allogeneic, cell-based uveal melanoma vaccines that activate CD4(+) T lymphocytes, wh
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。